Drug updated on 10/29/2024
| Dosage Form | Injection (intravenous; 100 mg lyophilized powder in a single-dose vial) |
| Drug Class | claudin 18.2-directed cytolytic antibodies |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive as determined by an FDA-approved test.
Latest News
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Vyloy (zolbetuximab-clzb) Prescribing Information. | 2024 | Astellas Pharma US, Inc. Northbrook, Illinois |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Clinical practice guidelines for esophagogastric junction cancer: Upper GI Oncology Summit 2023. | 2024 | Gastric Cancer |
| Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer. | 2024 | ESMO Open |